EXTH-50. DEVELOPMENT OF INVESTIGATOR INITIATED CLINICAL TRIAL OF TERT-TARGETING THERAPY USING ERIBULIN MESYLATE IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Despite of recent intense investigations, no effective molecular targeting therapy has been successfully developed in patients with glioblastomas (GBMs). Approximately 60–80% of GBM harbor mutations in the promoter region of telomerase reverse transcriptase (TERT), which leads to its upregulation. I...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Takahashi, Masamichi, Miki, Shunichiro, Fukuoka, Kohei, Maida, Yoshiko, Hayashi, Mitsuhiro, Hamada, Akinobu, Nishikawa, Ryo, Nagane, Motoo, Maruyama, Takashi, Mukasa, Akitake, Arakawa, Yoshiki, Arita, Hideyuki, Kitamura, Natsuko, Yonemori, Kan, Tamura, Kenji, Masutomi, Kenkichi, Narita, Yoshitaka, Ichimura, Koichi
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2017
נושאים:
Abstracts
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692632/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.342
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים